Literature DB >> 17055696

Protective effect of beta-glucan extracted from Saccharomyces cerevisiae, against DNA damage and cytotoxicity in wild-type (k1) and repair-deficient (xrs5) CHO cells.

Rodrigo Juliano Oliveira1, Renata Matuo, Ariane Fernanda da Silva, Hevenilton José Matiazi, Mário Sérgio Mantovani, Lúcia Regina Ribeiro.   

Abstract

A large number of functional foods, including those that contain beta-glucan, have been shown to prevent the development of cancer and other chronic diseases. The aim of the present study was to elucidate its mechanism of action, as well as to understand its effects as an antigenotoxic, anticlastogenic agent, and to determine its capacity to preserve cell viability. The investigation was carried out in the CHO-k1 and CHO-xrs5 cell lines. The cytokinesis-blocked micronucleus assay indicated that the different doses of beta-glucan examined (5, 10, 20 and 40 microg/ml) did not show clastogenic effects. In the CHO-k1 cell line, a chemopreventive effect could be observed in all the protocols tested: pre-treatment (% reduction of 35.0-57.3), simultaneous treatment (simple--5 reduction of 19.7-55.6 and with pre-incubation--of 42.7-56.4) and post-treatment (% reduction of 17.9-37.6). This finding indicates mechanisms of action involving desmutagenesis and bioantimutagenesis, albeit the latter having a lesser role. However, in the repair-deficient CHO-xrs5 cells, beta-glucan did not show a protective effect with post-treatment (% reduction of 2.96), thus supporting the involvement of bioantimutagenesis. The comet assay in CHO-k1 cells demonstrated that beta-glucan has neither a genotoxic nor an antigenotoxic effect. Cell viability tests indicated that beta-glucan preserves cell viability in both cell lines, preventing apoptotic events. These findings suggest that beta-glucan, when present in foods, could provide them with nutraceutical characteristics and act as a dietary supplement, or that beta-glucan could be used in new drug development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17055696     DOI: 10.1016/j.tiv.2006.07.018

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  12 in total

1.  Anticlastogenic effect of β-glucan, extracted from Saccharomyces cerevisiae, on cultured cells exposed to ultraviolet radiation.

Authors:  Ariane Fernanda da Silva; Rodrigo Juliano Oliveira; Andressa Megumi Niwa; Gláucia Fernanda Rocha D'Epiro; Lúcia Regina Ribeiro; Mário Sérgio Mantovani
Journal:  Cytotechnology       Date:  2012-06-09       Impact factor: 2.058

Review 2.  Effects of glucan on bone marrow.

Authors:  Petr Sima; Luca Vannucci; Vaclav Vetvicka
Journal:  Ann Transl Med       Date:  2014-02

3.  PRAP1 is a novel executor of p53-dependent mechanisms in cell survival after DNA damage.

Authors:  B H Huang; J L Zhuo; C H W Leung; G D Lu; J J Liu; C T Yap; S C Hooi
Journal:  Cell Death Dis       Date:  2012-12-13       Impact factor: 8.469

4.  Protective effect of carboxymethyl-glucan (CM-G) against DNA damage in patients with advanced prostate cancer.

Authors:  Marciane Magnani; Raul Jorge Hernan Castro-Gomez; Mateus Prates Mori; Hellen Kuasne; Emerson Pereira Gregório; Farid Libos; Ilce Mara de Syllos Cólus
Journal:  Genet Mol Biol       Date:  2011-03-01       Impact factor: 1.771

5.  Effects of β-glucan polysaccharide revealed by the dominant lethal assay and micronucleus assays, and reproductive performance of male mice exposed to cyclophosphamide.

Authors:  Rodrigo Juliano Oliveira; João Renato Pesarini; Maria José Sparça Salles; Tatiane Yumi Nakamura Kanno; Ana Carolina Dos Santos Lourenço; Véssia da Silva Leite; Ariane Fernanda da Silva; Hevenilton José Matiazi; Lúcia Regina Ribeiro; Mário Sérgio Mantovani
Journal:  Genet Mol Biol       Date:  2013-02-28       Impact factor: 1.771

6.  Cardanol: toxicogenetic assessment and its effects when combined with cyclophosphamide.

Authors:  Beatriz Ursinos Catelan Schneider; Alisson Meza; Adilson Beatriz; João Renato Pesarini; Pamela Castilho de Carvalho; Mariana de Oliveira Mauro; Caroline Bilhar Karaziack; Andréa Luiza Cunha-Laura; Antônio Carlos Duenhas Monreal; Renata Matuo; Dênis Pires de Lima; Rodrigo Juliano Oliveira
Journal:  Genet Mol Biol       Date:  2016 Apr-Jun       Impact factor: 1.771

7.  Mesenchymal stem cell therapy promotes the improvement and recovery of renal function in a preclinical model.

Authors:  Antônio Urt-Filho; Rodrigo Juliano Oliveira; Larissa Correa Hermeto; João Renato Pesarini; Natan de David; Wilson de Barros Cantero; Gustavo Falcão; Guido Marks; Andréia Conceição Milan Brochado Antoniolli-Silva
Journal:  Genet Mol Biol       Date:  2016-06-03       Impact factor: 1.771

Review 8.  Clinical and Physiological Perspectives of β-Glucans: The Past, Present, and Future.

Authors:  Khawaja Muhammad Imran Bashir; Jae-Suk Choi
Journal:  Int J Mol Sci       Date:  2017-09-05       Impact factor: 5.923

9.  In vivo evaluation of the antimutagenic and antigenotoxic effects of β-glucan extracted from Saccharomyces cerevisiae in acute treatment with multiple doses.

Authors:  Rodrigo Juliano Oliveira; Maria José Sparça Salles; Ariane Fernanda da Silva; Tatiane Yumi Nakamura Kanno; Ana Carolina Dos Santos Lourenço; Véssia da Silva Leite; Hevenilton José Matiazi; João Renato Pesarini; Lúcia Regina Ribeiro; Mário Sérgio Mantovani
Journal:  Genet Mol Biol       Date:  2013-07-19       Impact factor: 1.771

10.  In vivo chemotherapeutic insight of a novel isocoumarin (3-hexyl-5,7-dimethoxy-isochromen-1-one): Genotoxicity, cell death induction, leukometry and phagocytic evaluation.

Authors:  Flávio Henrique Souza de Araújo; Débora Rojas de Figueiredo; Sarah Alves Auharek; João Renato Pesarini; Alisson Meza; Roberto da Silva Gomes; Antônio Carlos Duenhas Monreal; Andréia Conceição Milan Brochado Antoniolli-Silva; Dênis Pires de Lima; Candida Aparecida Leite Kassuya; Adilson Beatriz; Rodrigo Juliano Oliveira
Journal:  Genet Mol Biol       Date:  2017 Jul-Sep 01       Impact factor: 1.771

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.